2-chloro-5-ethyl-3-methylpyridine | 1351168-93-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-chloro-5-ethyl-3-methylpyridine
• 英文别名: 2-Chloro-5-ethyl-3-methylpyridine
• CAS: 1351168-93-8
• 化学式: C₈H₁₀ClN
• 分子量: 155.627
• InChiKey: SQTOQUJZHCEURC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-chloro-5-ethyl-3-methylpyridine 、 (S)-3-(2-fluoro-4-(methylsulfonyl)phenylamino)-1-(piperidin-4-yl)pyrrolidin-2-one 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 caesium carbonate 作用下， 以 甲苯 为溶剂， 以23%的产率得到1-(1-(5-ethyl-3-methylpyridin-2-yl)piperidin-4-yl)-3-(2-fluoro-4-(methylsulfonyl)phenylamino)pyrrolidin-2-one
  参考文献：
  名称：

  [EN] PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS
  [FR] LACTAMES À SUBSTITUTION PIPÉRIDINYLE COMME MODULATEURS DE GPR119

  摘要：

  式（I）的化合物及其药学上可接受的盐，其中X1、X2、L、R3、R4、R5、R6、R6a、R7、R9、R9a和n的含义如规范中所述，是GPR119的调节剂，并且在治疗或预防诸如但不限于2型糖尿病、糖尿病并发症、糖尿病症状、代谢综合征、肥胖、血脂异常及相关疾病方面具有用处。

  公开号：

  WO2011146335A1

文献信息

• PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS
  申请人：Global Blood Therapeutics, Inc.

  公开号：US20150315198A1

  公开（公告）日：2015-11-05

  In one aspect this invention relates generally to compounds of Formula: and sub-formulas thereof, or a tautomer of each thereof, a pharmaceutically acceptable salt of each thereof, or a pharmaceutically acceptable solvate of each of the foregoing, where X 1 , L 1 , L 3 , and R 3 are described herein.

  在一个方面，这项发明通常涉及以下式的化合物： 及其亚式，或每个亚式的重排异构体，每个的药学上可接受的盐，或每个前述的药学上可接受的溶剂，其中X 1 ，L 1 ，L 3 和R 3 如本文所述。
• PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS
  申请人：Aicher Thomas Daniel

  公开号：US20130158009A1

  公开（公告）日：2013-06-20

  Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which X 1 , X 2 , L, R 3 , R 4 , R 5 , R 6 , R 6a , R 7 , R 9 , R 9a , and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.

  公式（I）的化合物及其药学上可接受的盐，其中X1、X2、L、R3、R4、R5、R6、R6a、R7、R9、R9a和n的含义如规范所述，是GPR119的调节剂，可用于治疗或预防疾病，例如但不限于2型糖尿病、糖尿病并发症、糖尿病症状、代谢综合征、肥胖症、血脂异常和相关疾病。
• Piperidinyl-substituted lactams as GPR119 modulators
  申请人：Aicher Thomas Daniel

  公开号：US08754226B2

  公开（公告）日：2014-06-17

  Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which X1, X2, L, R3, R4, R5, R6, R6a, R7, R9, R9a, and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.

  公式（I）的化合物及其药学上可接受的盐，其中X1、X2、L、R3、R4、R5、R6、R6a、R7、R9、R9a和n的含义如规范所示，是GPR119的调节剂，可用于治疗或预防诸如2型糖尿病、糖尿病并发症、糖尿病症状、代谢综合征、肥胖症、血脂异常和相关疾病等疾病。
• PROTON PUMP INHIBITORS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1803709A1

  公开（公告）日：2007-07-04

  A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof. or a prodrug thereof is provided.

  一种质子泵抑制剂，含有由式 (I) 代表的化合物 其中 X 和 Y 相同或不同，并且各自是键或在主链中具有 1 至 20 个碳原子的间隔物，R1 是任选取代的烃基或任选取代的杂环基，R2、R3 和 R4 相同或不同，并且各自是氢原子、任选取代的烃基、任选取代的噻吩基、任选取代的苯并[b]噻吩基、任选取代的呋喃基、任选取代的吡啶基、任选取代的吡唑基、任选取代的嘧啶基、酰基、卤素原子、氰基或硝基，R5 和 R6 相同或不同，且各自为氢原子或任选取代的烃基，在体内转化为质子泵抑制剂后具有优异的质子泵作用并显示出抗溃疡活性等，或其盐。或其原药。
• Viral polymerase inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2626354A1

  公开（公告）日：2013-08-14

  An enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein, or a salt or ester thereof, as an inhibitor of HCV NS5B polymerase.

  式 I 所代表化合物的对映体、非对映异构体或同系物： 其中 A、B、R1、R2、R3、R4、R5、R6、R7、R8、R9 和 R10 如本文所定义，或其盐或酯，作为 HCV NS5B 聚合酶的抑制剂。